Vestal Point Capital’s Solid Biosciences SLDB Stock Holding History

Vestal Point Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.6M	Sell	2,160,000 -2,840,000	-57%	-$21.5M	0.5%	42
2026 Q1	$36M	Sell	5,000,000 -815,000	-14%	-$5.24M	1.01%	35
2025 Q4	$32.8M	Buy	5,815,000 +2,840,000	+95%	+$15.4M	1.12%	28
2025 Q3	$18.4M	Buy	2,975,000 +1,470,000	+98%	+$8.6M	0.83%	42
2025 Q2	$7.33M	Sell	1,505,000 -248,558	-14%	-$879K	0.39%	48
2025 Q1	$6.49M	Sell	1,753,558 -1,096,442	-38%	-$4.69M	0.46%	40
2024 Q4	$11.4M	Buy	2,850,000 +50,000	+2%	+$275K	0.68%	41
2024 Q3	$19.5M	Buy	2,800,000 +135,000	+5%	+$1.09M	1.48%	23
2024 Q2	$15.1M	Buy	2,665,000 +1,630,000	+157%	+$14.6M	1.13%	29
2024 Q1	$13.8M	Buy	1,035,000 +1,000,915	+2,937%	+$9.37M	1.14%	22
2023 Q4	$209K	Buy	+34,085	New	+$109K	0.02%	46

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vestal Point Capital's SLDB Position: Q2 2026 in Review

Vestal Point Capital reduced its Solid Biosciences (SLDB) stake by 57% in Q2 2026, selling an estimated $21.5M and leaving 2,160,000 shares worth $21.6M. The position accounts for 0.5% of the portfolio, ranked #42.

Vestal Point Capital first reported a position in SLDB in Q4 2023 and has held it in 11 quarters since. The position peaked at $36M in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Vestal Point Capital held 2,160,000 shares of Solid Biosciences worth $21.6M as of Q2 2026.
Vestal Point Capital sold 2,840,000 Solid Biosciences shares in Q2 2026, an estimated $21.5M.
Solid Biosciences made up 0.5% of Vestal Point Capital's portfolio in Q2 2026, its #42 holding.
Vestal Point Capital first reported a position in Solid Biosciences in Q4 2023 and has held it in 11 quarters since.
Vestal Point Capital's Solid Biosciences position peaked at $36M in Q1 2026.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.